Talaromyces marneffei, Coccidioides species, and Paracoccidioides species-a systematic review to inform the World Health Organization priority list of fungal pathogens.

Autor:	Morris AJ; Department of Microbiology, Auckland City Hospital, Te Toku Tumai, Grafton, Auckland, New Zealand., Kim HY; The University of Sydney, Infectious Diseases Institute (Sydney ID), New South Wales, Australia.; Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia.; Westmead Hospital, Westmead, New South Wales, Australia., Nield B; Department of Infectious Diseases and Microbiology, Royal Prince Alfred Hospital, Sydney, Australia., Dao A; The University of Sydney, Infectious Diseases Institute (Sydney ID), New South Wales, Australia.; Westmead Hospital, Westmead, New South Wales, Australia.; Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia.; Children's Hospital at Westmead, Westmead, New South Wales, Australia., McMullan B; School of Clinical Medicine, University of New South Wales, Sydney, New South Wales, Australia.; Department of Infectious Diseases, Sydney Children's Hospital, Randwick, New South Wales, Australia.; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Alastruey-Izquierdo A; Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain., Colombo AL; Departamento de Medicina, Division of Infectious Diseases, Hospital São Paulo, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil., Heim J; Global Antibiotics Research and Development Partnership, Drugs for Neglected Diseases Initiative, Geneva, Switzerland., Wahyuningsih R; Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.; Department of Parasitology, Faculty of Medicine, Universitas Kristen, Jakarta, Indonesia., Le T; Division of Infectious Diseases and International Health, Duke University School of Medicine, Durham, NC, USA.; Tropical Medicine Research Center for Talaromycosis, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam., Chiller TM; Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA., Forastiero A; Department of Communicable Diseases Prevention, Control and Elimination, Pan American Health Organization,Washington, DC, USA., Chakrabarti A; Doodhadhari Burfani Hospital and Research Institute, Haridwar, India., Harrison TS; Institute for Infection and Immunity, and Clinical Academic Group in Infection and Immunity, St. George's, University of London, and St. George's University Hospitals NHS Foundation Trust, London, UK.; MRC Centre for Medical Mycology, University of Exeter, Exeter, UK., Bongomin F; Department of Medical Microbiology and Immunology, Faculty of Medicine, Gulu University, Gulu, Uganda., Galas M; Antimicrobial Resistance Special Program, Communicable Diseases and Environmental Determinants of Health, Pan American Health Organization, Washington, DC, USA., Siswanto S; World Health Organization, South-East Asia Region Office, New Delhi, India., Dagne DA; Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland., Roitberg F; Department of Noncommunicable Diseases, World Health Organization, Geneva, Switzerland., Gigante V; Impact Initiatives and Research Coordination Unit, Global Coordination Department, Antimicrobial Resistance Division, World Health Organization, Geneva, Switzerland., Beardsley J; The University of Sydney, Infectious Diseases Institute (Sydney ID), New South Wales, Australia.; Westmead Institute for Medical Research, Westmead, New South Wales, Australia., Sati H; Impact Initiatives and Research Coordination Unit, Global Coordination Department, Antimicrobial Resistance Division, World Health Organization, Geneva, Switzerland., Alffenaar JW; The University of Sydney, Infectious Diseases Institute (Sydney ID), New South Wales, Australia.; Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia.; Westmead Hospital, Westmead, New South Wales, Australia., Morrissey CO; Department of Infectious Diseases, The Alfred and Monash University, Melbourne, Victoria, Australia.
Jazyk:	angličtina
Zdroj:	Medical mycology [Med Mycol] 2024 Jun 27; Vol. 62 (6).
DOI:	10.1093/mmy/myad133
Abstrakt:	The World Health Organization, in response to the growing burden of fungal disease, established a process to develop a fungal pathogen priority list. This systematic review aimed to evaluate the epidemiology and impact of infections caused by Talaromyces marneffei, Coccidioides species, and Paracoccidioides species. PubMed and Web of Sciences databases were searched to identify studies published between 1 January 2011 and 23 February 2021 reporting on mortality, complications and sequelae, antifungal susceptibility, preventability, annual incidence, and trends. Overall, 25, 17, and 6 articles were included for T. marneffei, Coccidioides spp. and Paracoccidioides spp., respectively. Mortality rates were high in those with invasive talaromycosis and paracoccidioidomycosis (up to 21% and 22.7%, respectively). Hospitalization was frequent in those with coccidioidomycosis (up to 84%), and while the duration was short (mean/median 3-7 days), readmission was common (38%). Reduced susceptibility to fluconazole and echinocandins was observed for T. marneffei and Coccidioides spp., whereas >88% of T. marneffei isolates had minimum inhibitory concentration values ≤0.015 μg/ml for itraconazole, posaconazole, and voriconazole. Risk factors for mortality in those with talaromycosis included low CD4 counts (odds ratio 2.90 when CD4 count <200 cells/μl compared with 24.26 when CD4 count <50 cells/μl). Outbreaks of coccidioidomycosis and paracoccidioidomycosis were associated with construction work (relative risk 4.4-210.6 and 5.7-times increase, respectively). In the United States of America, cases of coccidioidomycosis increased between 2014 and 2017 (from 8232 to 14 364/year). National and global surveillance as well as more detailed studies to better define sequelae, risk factors, outcomes, global distribution, and trends are required. (© The Author(s) 2023. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu